Annals of RSCB Vol. XVII, Issue 1/2012
|
|
- Phyllis Sullivan
- 5 years ago
- Views:
Transcription
1 CORRELATIONS BETWEEN ENDOTHELIAL DYSFUNCTION AND GLYCEMIA IN VENOUS THROMBOSIS PATHOGENESIS Codruţa Bădescu 1, Oana Bădulescu 2, Manuela Ciocoiu 2, Magda Bădescu 2, M. Costuleanu 2 1 DEPARTMENT OF INTERNAL MEDICINE, 2 DEPARTMENT OF PATHOPHYSIOLOGY, UNIVERSITY OF MEDICINE AND PHARMACY "GRIGORE T. POPA" IASI Summary Venous thromboembolism (VTE), including deep venous thrombosis (DVT) is a major cause of morbidity and death. Thrombus formation and propagation depend on the presence of abnormalities of blood flow, blood vessel wall, and blood inflamatory components, known collectively as Virchow's triad. Epidemiologic studies consider vascular complications as the first cause of death in diabetic patients. The objective of this study was to determine the thrombotic risk in patients with type 2 diabetes mellitus (DM) with or without VTE compared with non-diabetic patients with VTE disease. The study comprises patients hospitalized in the Second Medical Clinic of the Sf. Spiridon Hospital between January 1, 5 and January 1, 211. The patients were investigated by determining two factors of coagulation profile: von Willebrand Factor (vwf) and DD-imers. The highest levels of the two studied parameters were found in the diabetic groups (DM+VTE) (p<,1) and (DM-VTE) (p<,5). The elevated levels of vwf and DD-imers in diabetic patients, reflect the effects of hyperglycemia on endothelium and the existence of platelet-vwf interaction, which would explain the accelerated venous thromboembolism in this patients. But diabetics vascular pathology it is also based on a lack of balance between the thrombosis-thrombolysis processes, to the benefit of thrombosis, followed by the occurrence of ischemic events Key words. thrombosis, von Willebrand Factor, DD-imers, hyperglycaemia. Introduction Venous thromboembolism is a frequent disease with an age-adjusted incidence of 1 to 2 events per of the general population and constitutes a major health care problem because of its high morbidity and mortality (Heit, 8). About one-third of patients suffering from a first episode of deep venous thrombosis (DVT) or pulmonary embolism (PE) develops a recurrence of VTE within 1 years (Heit et al., 2). From a clinical perspective, it would be extremely helpful to have biomarkers that enable early identification of patients at high or low risk of primary and recurrent VTE and allow prompt diagnosis and therapy assessment. Venous thromboembolism results from a combination of hereditary and acquired risk 143 magda.badescu@gmail.com factors, also known as thrombophilia or hypercoagulable states. In addition, vessel wall damage, venous stasis, and increased activation of clotting factors first described by Rudolf Virchow more than a century ago still remain the fundamental basis for our understanding of thrombosis. Virchow proposed that 3 elements venous stasis, endothelial injury, and hypercoagulability were the major factors responsible for the development of VTE (Snow et al., 7). Since that time, the role of each of these elements of the triad have been extensively evaluated, venous thromboembolism is associated with nearly a doubling in the risk for death among diabetic patients. The venous endothelium is thrombogenically inactive, yet its injury
2 exposes the subendothelial layers, which come into contact with the blood. The thrombus occurs further to coagulation cascade activation (Ageno et al., 8). Altered blood composition (hyperlipoproteinemia, polycythemia, inflammation) is associated with a high risk of thrombosis. In order to fulfill its function, the endothelium produces a variety of mediators-regulators including the von Willebrand factor (VWF), adhesion molecules and DD-imers (Wells et al., 3). Material and methods The study comprises patients (Women 135, Men 115) hospitalized in the Second Medical Clinic of the Sf. Spiridon Hospital between January 1, 5 and January 1, 211. The patients were distributed in the following groups: - group 1 Diabetic women with venous thromboembolism (DM+VTE), - group 2 Diabetic women without venous thromboembolism (DM-VTE), - group 3 Diabetic men with clinical venous thromboembolism (DM+VTE), - group 4 Diabetic men without venous thromboembolism (DM-VTE), - group 5 Non-diabetic women with venous thromboembolism (VTE), - group 6 Non-diabetic men with venous thromboembolism (VTE), The major objective of our study was: the determination of the thrombotic risk in patients with type 2 diabetes mellitus with or without venous thromboembolism compared with non-diabetic patients with venous thromboembolism. In the studied group, we followed the values of two parameters (von Willebrand factor and DDimers), in correlation with the duration of the diabetes mellitus. Results and disscussions The women had had diabetes for 2 to 1 years, exhibiting high value dispersion (32.8 vs CV%), whereas the men had had it for 2 to 9 years, also exhibiting 144 high value series dispersion (31.42 vs CV%). Comparisons between the Von Willebrand factor (vwf) values in women revealed the most homogeneous individual values in DVT diabetic women (13.3 CV%). In the women s groups, all the 1 cases exhibited vwf values higher than normal (16%), and no significance tests could be performed. r= Duration of the disease - Age Diabetic women with VTE r= Duration of the disease - Age Diabetic women without VTE r= Non-diabetic women with VTE Fig.1: Correlation between the Von Willebrand factor (%) and patients age
3 There is no significant correlation between the vwf factor and the age of the women patients in the three study groups, as they are independent variables in the deep vein thrombosis groups and they establish a poor direct correlation in the group of diabetic women without VTE. In the VTE diabetic women group, the vwf factor is directly correlated with the history of diabetes (r=.86), which points out that high vwf values are significantly associated with a long history of diabetes, whereas in women without VTE, high vwf values are detected in patients with a short history of diabetes, and the correlation is indirect (r = -.22). r= diabetic men with VTE The comparisons between the Von Willebrand factor (vwf) values conducted in men have the same outcome as the same comparisons carried out in women: the most homogeneous individual Von Willebrand factor values are reported in the VTE diabetic men group (28.47 CV%). r= diabetic men without VTE 145 r= nondiabetic m en w ith VTE Fig.2: Correlation between the Von Willebrand factor (%) and patients age The values of this parameter are above normal (16%) in diabetic men, i.e. in 9 and 8 cases, respectively, yet when compared with the group of non-diabetic men (5 cases above normal) the difference is not statistically significant (χ 2 =4.43; GL=2; p=.19). The vwf factor exhibits no significant correlation with the age of the patients in the three study groups; it establishes a poor direct correlation with age in the VTE diabetic patient group and indirect correlations in the other groups (Stegenga et al., 6). In the VTE diabetic men group, the vwf factor establishes a poor direct correlation with the history of diabetes (r=.21), whereas in diabetic patients without CI, the high vwf values are moderately associated with a longer history of diabetes (r =.59). The average vwf values reveal no significant differences either between the two sexes, or between the study groups. As concerns the von Willebrand factor, there is currently no data supporting the assumption according to which a high von Willebrand factor level in the plasma is
4 a risk factor for deep venous thrombosis. When considered from the viewpoint of this assumption related to VWF significance, the values we recorded are not surprising. The higher plasma levels are probably the expression of the endotheliopathy characterizing the prothrombotic status (Geerts et al., 8). The highest values were reported in the group of diabetic patients who also suffered from deep venous thrombosis. As far as the group of diabetic patients without venous complications is concerned, one may assume the existence of vascular involvement manifested subclinically, especially since it has been proven that endotheliopathy precedes not only the onset of cardiovascular diseases, but also the onset of diabetes mellitus (the synthesis and release of glycoproteins of endothelial origin are stimulated by metabolic disorders (Tamariz et al., 4). DD-imers In men, it was observed that DDimers had the most homogeneous individual values in group of diabetic men with venous thromboembolism (DM+VTE)(6,88CV%). a direct correlation with the duration of the disease (r=,23) it was observed in group of diabetic men with venous thromboembolism (DM+VTE); an indirect correlation (r = -,42) it was observed in diabetic men without venous thromboembolism (DM -VTE); The mechanisms linking the elevated levels of DD-imers to insulin resistance and type 2 diabetes may be related to the presence of underlying endothelial dysfunction and or inflammation, both of which are involved in the development of insulin resistance (Eichinger et al., 8) r= duration of the disease (years) diabetic men with VTE r= duration of the disease (years) diabetic men without VTE Fig.3: Correlations between DD-imers values () and the duration of the DM, in men In women, DD-imers had the most homogeneous individual values in the group of diabetic women without venous thromboembolism(dm- VTE)(16,22CV%). it was observed an direct correlation (r=,58) with the duration of the disease in diabetic women with venous thromboembolism (DM+VTE); the DDimers' values increase with the history of DM. in the group of diabetic women without venous thromboembolism (DM- VTE) it was observed a indirect correlation (r = -,24) with the duration of the disease; In vitro, glycated albumin has been reported to increase tissue factor expression in umbilical vein endothelial cells to indicate a mechanism by which glycation might initiate coagulation processes (Righini et al., 8). 146
5 r= duration of the disease 15 diabetic women with VTE r= duration of the disease (years) diabetic women without VTE Fig.4: Correlations between DD-imers values () and the duration of the DM, in women Regarding the values of DD-imers', these presented the following differences: there were not significant differences between genders; in women, diabetic patients with venous thromboembolism (DM+VTE) have significantly higher mean values than diabetic patients without venous thromboembolism (DM-VTE) (p<,5) ; in men, no significant differences were recorded in mean values of DD-imers, in the studied groups. The elevated levels of vwf and DD-imers are an indication of endothelial cell damage and are correlated with other cardiovascular risk factors (Wakefield et al., 8). Many studies have reported an association between elevated FVIII and/or vwf levels, the presence of VTE disease (Cosmi et al., 8) and the risk of future cardiovascular events in patients with VTE (Eichinger et al., 3). The mechanisms linking the elevated levels of vwf DDimers to insulin resistance and type 2 diabetes may be related to the presence of underlying endothelial dysfunction and or inflammation, both of which are involved in the development of insulin resistance. Hyperglycemia per se has been implicated in the development of prothrombotic changes in clamp studies (Stegenga et al., 6) where under conditions of euinsulinaemic hyperglycemia, twofold increases in thrombin antithrombin complexes and circulating soluble tissue factor were documented. Hyperinsulinemia in the presence of euglycaemia led to increases in vwf, and the authors made the observation that glucose modulated thrombotic processes whilst insulin regulated fibrinolysis. In vitro, glycated albumin has been reported to increase tissue factor expression in both monocytes and umbilical vein endothelial cells to indicate a mechanism by which glycation might initiate coagulation processes. Association studies in nondiabetic subjects have indicated correlations between serum advanced glycation end products (AGE) and both vwf and DD-imers levels to support the concept that AGE accumulation may stimulate prothrombotic changes in man. In addition, higher levels of glycation were associated with endothelial cell apoptosis which might contribute to vascular damage (Verhovsek et al., 8. Visceral fat produces proinflammatory cytokines such as interleukin-6 and TNF-α, which in turn elevate fibrinogen levels. These cytokines are responsible for some of the endothelial dysfunction that causes an increase in vwf. There is also some experimental evidence to support the notion that the coagulopathy is driven by hyperglycemia rather than hyperinsulinemia (Stegenga et al., 6). Conclusions The assessment of the blood flow, vascular reactivity and certain endothelial dysfunction markers has been shown to be associated with an unfavorable cardiovascular prognosis. In DM, 147
6 hyperglycemia and the metabolic syndrome components directly or indirectly cause endothelial dysfunction. The development of endothelial dysfunction, in pacients with type 2 diabetes mellitus, promotes vasospasm, thrombosis and inflammation, processes that may all be involved in the early stages of VTE disease, a view supported by clinical studies. DM is by itself a major thrombosis risk factor. The risk of developing cardiovascular events is higher in DM patients, because hyperglycemia determines subsequent metabolic disorders, by forming AGE and then by triggering quantitative and qualitative changes in serum lipoproteins, mechanisms which would explain the atherosclerosis acceleration in these patients. References Ageno W., Becattini C., Brighton.T,: Cardiovascular risk factors and venous thromboembolism: A meta-analysis. Circulation., 117: (1): 93-12, 8. Cosmi B., Legnani C., Cini M. D-dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. Thromb. Res.; 122: , 8. Eichinger S., Hron G., Kollars M.: Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer. Clin. Chem.; 54: , 8. Eichinger S., Minar E., Bialonczyk C.: D-dimer levels and risk of recurrent venous thromboembolism. JAMA.; 29: , 3. Geerts W.H., Berqqvist D., Pineo G.F.,: Prevention of venous thromboembolism: American College of Chest. Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest., 133: (6 Suppl): 381S- 453S, 8. Heit J.A., O Fallon W.M., Petterson T.M.: Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: A population-based study. Arch. Intern. Med., 162: (11): , 2. Heit J.A., The epidemiology of venous thromboembolism in the community. Arterioscler Thromb. Vasc. Biol.; 28: , Righini M., Perrier A., De Moerloose P. et al.: D-Dimer for venous thromboembolism diagnosis: 2 years later. J. Thromb. Haemost.; 6: , 8. Snow V., Qaseem A., Barry P.: Management of venous thromboembolism: A clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann. Intern. Med., 146:(3): 24-21, 7. Stegenga M.E., van der Crabben S.N., Levi M.. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes; 55: , 6. Tamariz L.J., Eng J., Segal J.B.: Usefulness of clinical prediction rules for the diagnosis of venous thromboembolism: A systematic review. Am. J. Med.;117: (9): , 4. Verhovsek M., Douketis J.D., Yi Q., Shrivastava S., Tait R.C., Baglin T., Poli D., Lim W.: Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann. Intern. Med.; 149: , W494; 8. Wakefield T.W., Myers D.D., Henke P.K.: Mechanisms of venous thrombosis and resolution. Arterioscler. Thromb.Vasc. Biol.; 28: ; 8. Wells P.S., Anderson D.R., Rodger M., Forgie M., Kearon C., Dreyer J., Kovacs G., Mitchell M., Lewandowski B., Kovacs M.J.; Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N. Engl. J. Med.; 349: ; 3.
Annals of RSCB Vol. XVI, Issue 1
THE STUDY OF PROTHROBOTIC STATE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASES Oana Bădulescu 1, Codruţa Bădescu 2, Manuela Ciocoiu 1, Magda Bădescu 1 1 DEPARTMENT OF PATHOPHYSIOLOGY;
More informationThrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI
Thrombophilia Diagnosis and Management Kevin P. Hubbard, DO, FACOI Clinical Professor of Medicine Kansas City University of Medicine and Biosciences-College of Osteopathic Medicine Kansas City, Missouri
More informationMenopausal Hormone Therapy & Haemostasis
Menopausal Hormone Therapy & Haemostasis The Haematologist Perspective Dr. Batia Roth-Yelinek Coagulation unit Hadassah MC Menopausal Hormone Therapy & Hemostasis Hemostatic mechanism Mechanism of estrogen
More informationPROGNOSIS AND SURVIVAL
CANCER ASSOCIATED THROMBOSIS PROGNOSIS AND SURVIVAL Since French internist Armand Trousseau reported the occurrence of mysterious thrombotic disorders in cancer patients in the mid-19th century, the link
More informationDVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center
DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients David Liff MD Oklahoma Heart Institute Vascular Center Overview Pathophysiology of DVT Epidemiology and risk factors for DVT in the
More informationVENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?
VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK? Ayman El-Menyar (1), MD, Hassan Al-Thani (2),MD (1)Clinical Research Consultant, (2) Head of Vascular Surgery, Hamad General Hospital
More informationWGA meeting Management and follow-up VTE in clinical pratice Dr Borgoens CHR Citadelle Liège
WGA meeting 2016 Management and follow-up VTE in clinical pratice Dr Borgoens CHR Citadelle Liège Clinical question Which complementary investigations are you going to plan during or early after hospitalization
More informationPOLYCYTHEMIA VERA SYNDROME-AS A PROTROMBOTHIC STATE
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2014 vol. 118. no. 2 BASIC SCIENCES ORIGINAL PAPERS POLYCYTHEMIA VERA SYNDROME-AS A PROTROMBOTHIC STATE Oana Viola Bădulescu 1, Manuela Ciocoiu 1, Iris Bararu 2 Mădălina
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/40114 holds various files of this Leiden University dissertation Author: Exter, Paul L. den Title: Diagnosis, management and prognosis of symptomatic and
More informationUnderstanding thrombosis in venous thromboembolism. João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal
Understanding thrombosis in venous thromboembolism João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal Disclosures João Morais On the last year JM received honoraria
More informationApproach to Thrombosis
Approach to Thrombosis Theera Ruchutrakool, M.D. Division of Hematology Department of Medicine Siriraj Hospital Faculty of Medicine Mahidol University Approach to Thrombosis Thrombosis: thrombus formation
More informationUC SF. Division of General Internal Medicine UNIVERSITY OF CALIFORNIA SAN FRANCISCO, DIVISION OF HOSPITAL MEDICINE
Updates in the Management of Venous Thromboembolism Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical Director, Anticoagulation Clinic Venous Thromboembolism
More informationDuration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016
Duration of Anticoagulant Therapy Linda R. Kelly PharmD, PhC, CACP September 17, 2016 Conflicts of Interest No conflicts of interest to report Objectives At the end of the program participants will be
More informationVENOUS THROMBOEMBOLISM: DURATION OF TREATMENT
VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT OBJECTIVE: To provide guidance on the recommended duration of anticoagulant therapy for venous thromboembolism (VTE). BACKGROUND: Recurrent episodes of VTE
More informationLa Trombosi Arteriosa
La Trombosi Arteriosa Prof. Giovanni Davì Medicina Interna Chieti Platelet activation and thrombosis Harrison 19 edizione Platelets are essential for primary hemostasis and repair of the endothelium They
More informationDave Duddleston, MD VP and Medical Director Southern Farm Bureau Life
Dave Duddleston, MD VP and Medical Director Southern Farm Bureau Life Sources of Risk for Venous Diseases Pulmonary embolism (thrombus) Bleeding from anticoagulation Mortality from underlying disease Chronic
More informationChapter. A higher risk of recurrent venous thrombosis in men is due to hormonal risk factors in women in thrombophilic families
Chapter A higher risk of recurrent venous thrombosis in men is due to hormonal risk factors in women in thrombophilic families Willem M. Lijfering Nic J.G.M. Veeger Saskia Middeldorp Karly Hamulyák Martin
More informationVTE in Children: Practical Issues
VTE in Children: Practical Issues Wasil Jastaniah MBBS,FAAP,FRCPC Consultant Pediatric Hem/Onc/BMT May 2012 Top 10 Reasons Why Pediatric VTE is Different 1. Social, ethical, and legal implications. 2.
More informationEpidemiologia e clinica del tromboembolismo venoso. Maria Ciccone Sezione di Ematologia e Fisiopatologia della Coagulazione
Epidemiologia e clinica del tromboembolismo venoso Maria Ciccone Sezione di Ematologia e Fisiopatologia della Coagulazione Thrombophilia may present clinically as one or more of several thrombotic manifestations
More informationTHROMBOPHILIA TESTING: PROS AND CONS SHANNON CARPENTER, MD MS CHILDREN S MERCY HOSPITAL KANSAS CITY, MO
THROMBOPHILIA TESTING: PROS AND CONS SHANNON CARPENTER, MD MS CHILDREN S MERCY HOSPITAL KANSAS CITY, MO DISCLAIMER I m a pediatrician I will be discussing this issue primarily from a pediatric perspective
More informationVenous thromboembolism (VTe) affects approximately
The Journal of The american osteopathic association Duration of Anticoagulation Treatment in Patients With Venous Thromboembolism Scott Kaatz, DO, MSc; Waqas Qureshi, MD; Christopher Fain, DO; and David
More informationRecurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism
ARTICLES Coagulation & its Disorders Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism Tom van der Hulle, Melanie Tan, Paul L. den Exter, Mark J.G.
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationChapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
More informationPathology of pulmonary vascular disease. Dr.Ashraf Abdelfatah Deyab. Assistant Professor of Pathology Faculty of Medicine Almajma ah University
Pathology of pulmonary vascular disease Dr.Ashraf Abdelfatah Deyab Assistant Professor of Pathology Faculty of Medicine Almajma ah University Pulmonary vascular disease Type of pulmonary circulation: Types
More informationSession Chair: Andrew I. Schafer, MD Speakers: Mary Cushman, MD, MSc; Paolo Prandoni, MD, PhD; and Thomas L. Ortel, MD, PhD
Thrombosis II Session Chair: Andrew I. Schafer, MD Speakers: Mary Cushman, MD, MSc; Paolo Prandoni, MD, PhD; and Thomas L. Ortel, MD, PhD Inherited Risk Factors for Venous Thrombosis Mary Cushman Venous
More informationInfections, inflammation and venous thrombosis; an epidemiological perspective Tichelaar, Ynse
University of Groningen Infections, inflammation and venous thrombosis; an epidemiological perspective Tichelaar, Ynse IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF)
More informationLow Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders
SURGICAL GRAND ROUNDS March 17 th, 2007 Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders Guillermo Escobar, M.D. LMWH vs UFH Jayer s sales pitch: FALSE LMW is
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationHemodynamic Disorders, Thrombosis, and Shock. Richard A. McPherson, M.D.
Hemodynamic Disorders, Thrombosis, and Shock Richard A. McPherson, M.D. Edema The accumulation of abnormal amounts of fluid in intercellular spaces of body cavities. Inflammation and release of mediators
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/21764 holds various files of this Leiden University dissertation. Author: Mos, Inge Christina Maria Title: A more granular view on pulmonary embolism Issue
More informationPredicting the risk of recurrent venous thromboembolism (VTE)
J Thromb Thrombolysis (2015) 39:353 366 DOI 10.1007/s19-015-1188-4 Predicting the risk of recurrent venous thromboembolism (VTE) Michael B. Streiff Published online: 27 February 2015 Ó Springer Science+Business
More informationHow long to continue anticoagulation after DVT?
How long to continue anticoagulation after DVT? Dr. Nihar Ranjan Pradhan M.S., DNB (Vascular Surgery), FVES(UK) Consultant Vascular Surgeon Apollo Hospital, Jubilee Hills, Hyderabad (Formerly Faculty in
More informationThe risk of recurrence in women with venous thromboembolism while using estrogens: a prospective cohort study
Journal of Thrombosis and Haemostasis, 12: 635 640 DOI: 10.1111/jth.12528 ORIGINAL ARTICLE The risk of recurrence in women with venous thromboembolism while using estrogens: a prospective cohort study
More informationInherited Thrombophilia Testing. George Rodgers, MD, PhD Kristi Smock MD
Inherited Thrombophilia Testing George Rodgers, MD, PhD Kristi Smock MD Prevalence and risk associated with inherited thrombotic disorders Inherited Risk Factor % General Population % Patients w/ Thrombosis
More informationThe Evidence Base for Treating Acute DVT
The Evidence Base for Treating Acute DVT Mr Chung Sim Lim Consultant Vascular Surgeon and Honorary Lecturer Royal Free London NHS Foundation Trust and University College London NIHR UCLH Biomedical Research
More informationConsultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5000
Consultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5000 Dorothy M. (Adcock) Funk, M.D. Karen A. Moser, M.D. Esoterix Coagulation September 20, 2013 Disclosures
More informationAre there still any valid indications for thrombophilia screening in DVT?
Carotid artery stenosis and risk of stroke Are there still any valid indications for thrombophilia screening in DVT? Armando Mansilha MD, PhD, FEBVS Faculty of Medicine of University of Porto Munich, 2016
More informationHaemostasis, thrombosis risk and hormone replacement therapy
Haemostasis, thrombosis risk and hormone replacement therapy Serge Motte Brussels 13.05.17 - MY TALK TODAY The coagulation cascade and its regulation Effects of hormone replacement therapy on haemostasis
More informationDuration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium
Duration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium Disclosures Honoraria and research support: Daiichi-Sankyo, Boehringer Ingelheim,
More informationThyroid disease and haemostasis: a relationship with clinical implications? Squizzato, A.
UvA-DARE (Digital Academic Repository) Thyroid disease and haemostasis: a relationship with clinical implications? Squizzato, A. Link to publication Citation for published version (APA): Squizzato, A.
More informationChoosing Wisely: If, When, What, and Who to Test for Thrombophilia
Choosing Wisely: If, When, What, and Who to Test for Thrombophilia Nicole Dodge Zantek, MD, PhD Medical Director, Special Coagulation Laboratory University of Minnesota Disclosures Financial interests
More informationThrombosis. By Dr. Sara Mohamed Abuelgasim
Thrombosis By Dr. Sara Mohamed Abuelgasim 1 Thrombosis Unchecked, blood coagulation would lead to dangerous occlusion of blood vessels if the protective mechanisms of coagulation factor inhibitors, blood
More informationP-Selectin as Predictor Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy
Hiroshima J. Med. Sci. Vol. 67, Special Issue, May, 018 1 P-Selectin as Predictor Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy C. SUHARTI *, SANTOSA, Eko Adhi PANGARSO, Budi SETIAWAN,
More informationTitle: Low Molecular Weight Heparins (LMWH), fondaparinux (Arixtra)
Origination: 03/29/05 Revised: 09/01/10 Annual Review: 11/20/13 Purpose: To provide guidelines and criteria for the review and decision determination of requests for medications that requires prior authorization.
More informationElevated D-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta-analysis
Journal of Thrombosis and Haemostasis, 7: 611 618 DOI: 10.1111/j.1538-7836.2009.03293.x ORIGINAL ARTICLE Elevated D-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a
More informationBo Tian, Chunfeng Song, Hui Li, Wenqian Zhang, Qirui Chen, Shuo Chen, Yili Fu, Xiaoxing Hu, Bin You, Tong Li, Bin Hu, Shengcai Hou
Original Article The significance of perioperative coagulation and fibrinolysis related parameters after lung surgery for predicting venous thromboembolism: a prospective, single center study Bo Tian,
More informationMutidisciplinary cooperation on VTE prevention and managment
Mutidisciplinary cooperation on VTE prevention and managment TAO YANG Dpartment of vascular surgery Shanxi DAYI Hospita Tai yuan Shanxi China Disclosure Speaker name: Tao Yang... I have the following potential
More informationChapter 1. Introduction
Chapter 1 Introduction Introduction 9 Even though the first reports on venous thromboembolism date back to the 13 th century and the mechanism of acute pulmonary embolism (PE) was unraveled almost 150
More informationDr. Pierpaolo Di Micco Internal Medicine and Emergency Room Fatebenefratelli Hospital of Naples, Italy
? Para què sirve el recuento de leucocitos en lospacientescon cancer? Dr. Pierpaolo Di Micco Internal Medicine and Emergency Room Fatebenefratelli Hospital of Naples, Italy ? Para què sirve el recuento
More informationHORMONES AND COAGULATION. Victor Gerdes Internist Slotervaart Hospital and Academic Medical Center Amsterdam
HORMONES AND COAGULATION Victor Gerdes Internist Slotervaart Hospital and Academic Medical Center Amsterdam Overview Introduction Thyroid hormone Cortisol Prolactin Implications VTE Risk Factors Genetic:
More informationAfter a first episode of acute venous thromboembolism
Predictive Value of D-Dimer Test for Recurrent Venous Thromboembolism After Anticoagulation Withdrawal in Subjects With a Previous Idiopathic Event and in Carriers of Congenital Thrombophilia Gualtiero
More informationTHE ROLE OF STATINS IN DEEP VEIN THROMBOSIS
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2012 vol. 116, no. 3 INTERNAL MEDICINE - PEDIATRICS UPDATES THE ROLE OF STATINS IN DEEP VEIN THROMBOSIS Maria-Magdalena Leon 1,4, Elena Cojocaru 2, Roxana Cobzaru 3,
More informationShould Patients with Venous Thromboembolism Be Screened for Thrombophilia?
REVIEW Should Patients with Venous Thromboembolism Be Screened for Thrombophilia? James E. Dalen, MD, MPH University of Arizona, Tucson. ABSTRACT In the mid-19th century, Virchow identified hypercoagulability
More informationWhat are blood clots?
What are blood clots? Dr Matthew Fay GP Principal The Willows Medical Practice- Queensbury GPwSI and Co-Founder Westcliffe Cardiology Service GP Partner Westcliffe Medical Group Created 5/31/18 Dr. Matthew
More informationWith the availability of new treatment
CMAJ Review Managing pulmonary embolism using prognostic models: future concepts for primary care Geert-Jan Geersing Md Phd, Ruud Oudega Md Phd, Arno W. Hoes Md Phd, Karel G.M. Moons Phd With the availability
More informationCANCER ASSOCIATED THROMBOSIS. Pankaj Handa Department of General Medicine Tan Tock Seng Hospital
CANCER ASSOCIATED THROMBOSIS Pankaj Handa Department of General Medicine Tan Tock Seng Hospital My Talk Today 1.Introduction 2. Are All Cancer Patients at Risk of VTE? 3. Should All VTE Patients Be Screened
More informationClinical Study Different Finite Durations of Anticoagulation and Outcomes following Idiopathic Venous Thromboembolism: A Meta-Analysis
Hindawi Publishing Corporation Thrombosis Volume 2010, Article ID 540386, 9 pages doi:10.1155/2010/540386 Clinical Study Different Finite Durations of Anticoagulation and Outcomes following Idiopathic
More informationUpdates in Management of Venous Thromboembolic Disease
Updates in Management of Venous Thromboembolic Disease November 7 th 2018 UHN Emergency Conference Susan Jenkins RN(EC) NP-Adult Thrombosis and Hemostasis Program University Health Network Disclosures
More informationGenetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수
Genetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수 Thrombophilia A hereditary or acquired disorder predisposing to thrombosis Questions Why should we test? Who should we test For what disorders?
More informationApproach to bleeding disorders &treatment. by RAJESH.N General medicine post graduate
Approach to bleeding disorders &treatment by RAJESH.N General medicine post graduate 2 Approach to a patient of bleeding diathesis 1. Clinical evaluation: History, Clinical features 2. Laboratory approach:
More informationIs thromboprophylaxis effective in reducing the pulmonary thromboembolism?
Is thromboprophylaxis effective in reducing the pulmonary thromboembolism? Fereshteh Rajabi (1), Masoumeh Sadeghi (2), Fereshteh Karbasian (3), Ali Torkan (4) Abstract BACKGROUND: Deep vein thrombosis
More informationThe risk of venous thromboembolism is markedly elevated in patients with diabetes
Diabetologia (2005) 48: 1017 1021 DOI 10.1007/s00125-005-1715-5 ARTICLE V. Petrauskiene. M. Falk. I. Waernbaum. M. Norberg. J. W. Eriksson The risk of venous thromboembolism is markedly elevated in patients
More informationVascular Medicine. Risk Assessment of Recurrence in Patients With Unprovoked Deep Vein Thrombosis or Pulmonary Embolism The Vienna Prediction Model
Vascular Medicine Risk Assessment of Recurrence in Patients With Unprovoked Deep Vein Thrombosis or Pulmonary Embolism The Vienna Prediction Model Sabine Eichinger, MD*; Georg Heinze, PhD*; Lisanne M.
More informationEpidermiology Early pulmonary embolism
Epidermiology Early pulmonary embolism Sitang Nirattisaikul Faculty of Medicine, Prince of Songkla University 3 rd most common cause of cardiovascular death in the United States, following ischemic heart
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationCausative factors of deep vein thrombosis of lower limb in Indian population
International Surgery Jthisnal Khadilkar R et al. Int Surg J. 18 Jan;(1):3-3 http://www.ijsurgery.com pissn 39-33 eissn 39-9 Original Research Article DOI: http://dx.doi.org/1.183/39-9.isj17919 Causative
More informationFocus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018
Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018 NO DISCLOSURE Pulmonary Embolism Venous thromboembolism (VT) is the third most common cause of cardiovascular
More informationVenous thromboembolism (VTE) is a common disease. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women
Menopause: The Journal of The North American Menopause Society Vol. 18, No. 5, pp. 488/493 DOI: 10.1097/gme.0b013e3181f9f7c3 * 2011 by The North American Menopause Society Hormone therapy and recurrence
More informationDISSEMINATED INTRAVASCULAR COAGULATION (DIC) Pichika Chantrathammachart MD Division of Hematology, Department of Medicine Ramathibodi Hospital
DISSEMINATED INTRAVASCULAR COAGULATION (DIC) Pichika Chantrathammachart MD Division of Hematology, Department of Medicine Ramathibodi Hospital Disseminated intravascular coagulation (DIC) Disseminated
More informationDuration of Therapy for Venous Thromboembolism
Duration of Therapy for Venous Thromboembolism Michael B Streiff, MD FACP Associate Professor of Medicine and Pathology Medical Director, Johns Hopkins Anticoagulation Service Chairman, VTE Guideline Committee
More informationInt J Clin Exp Med 2015;8(4): /ISSN: /IJCEM
Int J Clin Exp Med 2015;8(4):6585-6591 www.ijcem.com /ISSN:1940-5901/IJCEM0005223 Original Article Comparison of peripheral blood T lymphocyte immune function among venous thromboembolism patients with
More informationCURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM. Gordon Lowe Professor of Vascular Medicine University of Glasgow
CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM Gordon Lowe Professor of Vascular Medicine University of Glasgow VENOUS THROMBOEMBOLISM Common cause of death and disability 50% hospital-acquired
More informationChallenges in Anticoagulation and Thromboembolism
Challenges in Anticoagulation and Thromboembolism Ethan Cumbler M.D. Assistant Professor of Medicine Hospitalist Medicine Section University of Colorado Denver May 2010 No Conflicts of Interest Objectives
More informationBacillopeptidase F Proprietary Blend (BFPB) A Natural Enzyme Extracted by a Patented Fermentation Production Process to Support Healthy Circulation
Bacillopeptidase F Proprietary Blend (BFPB) A Natural Enzyme Extracted by a Patented Fermentation Production Process to Support Healthy Circulation What is Plasmanex1? Plasmanex1 is a dietary supplement
More informationDuration of Anticoagulation: Applying the Guidelines and Beyond
ISSUES IN THROMBOSIS MANAGEMENT AND ANTICOAGULATION Duration of Anticoagulation: Applying the Guidelines and Beyond Kenneth A. Bauer 1,2 1 Hematology Section, VA Boston Healthcare System and Beth Israel
More informationPlatelet function in diabetes
Platelet function in diabetes Agneta Siegbahn, MD, PhD, FESC Professor Clinical Coagulation Science Department of Medical Sciences and Uppsala Clinical Research Center Uppsala University Disclosures: None
More informationPaolo Prandoni Università di Padova
Paolo Prandoni Università di Padova Il domani doloroso della TVP FCSA, Bologna 2014 Teatro Anatomico Università di Padova Eventi attesi a distanza da un evento tromboembolico venoso Recidiva di TEV PTS
More information8,9,10. Deep venous thrombosis (DVT) is clotting of blood in a deep vein of Pulmonary embolism
CANCER ASSOCIATED THROMBOSIS DIAGNOSIS OF VTE In patients with cancer-associated thrombosis, landmark studies have demonstrated that effective prophylaxis and treatment of thrombosis reduces morbidity
More informationWhat is the optimal time window for treating deep venous thrombosis? Acute vs subacute vs chronic
What is the optimal time window for treating deep venous thrombosis? Acute vs subacute vs chronic Peter A. Schneider, MD Chief of Vascular Therapy Kaiser Foundation Hospital Honolulu, Hawaii Disclosure
More informationΜακροχρόνια παρακολούθηση ασθενών με πνευμονική εμβολή
Μακροχρόνια παρακολούθηση ασθενών με πνευμονική εμβολή Ευφροσύνη Δ. Μάναλη Λέκτορας Β Πανεπιστημιακή Πνευμονολογική Κλινική ΓΝΑ «Αττικόν» Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών Existing guidelines
More informationHemostasis. PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures
Hemostasis PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures Disorders of Hemostasis - Hemophilia - von Willebrand Disease HEMOPHILIA A defect in the thrombin propagation phase
More informationVenous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community
Venous Thrombosis Venous Thrombosis It occurs mainly in the deep veins of the leg (deep vein thrombosis, DVT), from which parts of the clot frequently embolize to the lungs (pulmonary embolism, PE). Fewer
More informationVenous thromboembolism is a common, potentially
CMAJ Research Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy Marc A. Rodger MD MSc, Susan R. Kahn MD MSc, Philip S. Wells MD MSc, David
More informationThrombosis. Jeffrey Jhang, M.D.
Thrombosis Jeffrey Jhang, M.D. Introduction The human hemostatic system has evolved to maintain blood flow under normal physiologic conditions while remaining primed to rapidly respond to vascular injury
More informationControversies in Venous Thromboembolism
Controversies in Venous Thromboembolism Menaka Pai, BSc MSc MD FRCPC Assistant Professor, Department of Medicine, McMaster University Associate Member, Department of Pathology and Molecular Medicine, McMaster
More informationThrombophilia. Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC. GASCO Atlanta Sept 8 th, Disclosures. Conflicts of interest: NONE
LA APLA 1 3 ACA Anti-ß2-GP I 2 45 Thrombophilia Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC GASCO Atlanta Sept 8 th, 2017 Disclosures Conflicts of interest: NONE Off-label product use discussion:
More informationWhat is the real place of venous echo Doppler in aircrew member flying rehabilitation after a thromboembolism event?
89 th ASMA ANNUAL SCIENTIFIC MEETING DALLAS- May 6-10, 2018 What is the real place of venous echo Doppler in aircrew member flying rehabilitation after a thromboembolism event? S BISCONTE (1), V MARICOURT
More informationCADTH Rapid Response Report: ASA for Venous Thromboembolism Prophylaxis: Evidence for Clinical Benefit and Harm
CADTH Rapid Response Report: ASA for Venous Thromboembolism Prophylaxis: Evidence for Clinical Benefit and Harm P. Timothy Pollak, MD, PhD University of Calgary Rocky Mountain/ACP Internal Medicine Meeting,
More informationHow to prevent thrombotic diseases? Sergio Fusco, MD
How to prevent thrombotic diseases? Sergio Fusco, MD Geriatric Division - Department of Internal Medicine Ospedale Dell'Angelo - Venice, Italy CONFLICT OF INTEREST DISCLOSURE I have no potential conflict
More informationWhat is the impact of Superficial Vein Thrombosis?
What is the impact of Superficial Vein Thrombosis? Athanasios D. Giannoukas MD, MSc(Lond.), PhD(Lond.), FEBVS Professor of Vascular Surgery Faculty of Medicine, University of Thessalia, Greece Chairman,
More informationVTE ACHIEVEMENTS AND CHALLENGES: 2012 AND BEYOND Samuel Z. Goldhaber, MD Director, VTE Research Group Cardiovascular Division Brigham and Women s
VTE ACHIEVEMENTS AND CHALLENGES: 2012 AND BEYOND Samuel Z. Goldhaber, MD Director, VTE Research Group Cardiovascular Division Brigham and Women s Hospital Professor of Medicine Harvard Medical School October
More informationDoes the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis
Journal of Thrombosis and Haemostasis, 8: 2436 2442 DOI: 10.1111/j.1538-7836.2010.04022.x ORIGINAL ARTICLE Does the clinical presentation and extent of venous thrombosis predict likelihood and type of
More informationClinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden
Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:
More informationThe Egyptian Journal of Hospital Medicine (Oct. 2015) Vol. 61, Page
The Egyptian Journal of Hospital Medicine (Oct. 2015) Vol. 61, Page 363-370 Validation of New D-Dimer Cutoff Values to Increase its Diagnostic Utility as Biochemical Marker in Acute Venous Thromboembolic
More informationVTE Management in Surgical Patients: Optimizing Prophylaxis Strategies
VTE Management in Surgical Patients: Optimizing Prophylaxis Strategies VTE in Surgical Patients: Recognizing the Patients at Risk Pathogenesis of thrombosis: Virchow s triad and VTE Risk Hypercoagulability
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationWhat s New in DVT & PE
What s New in DVT & PE Mark Buch MD CM CCFP(EM) Attending physician Emergency Department Jewish General Hospital Family Physician and Medical Director GMF Santé Mont-Royal Objectives: Review the diagnostic
More informationElevated Plasma Factor VIII and d-dimer Levels as Predictors of Poor Outcomes of Thrombosis in Children
The new england journal of medicine original article Elevated Plasma Factor VIII and d-dimer Levels as Predictors of Poor Outcomes of Thrombosis in Children Neil A. Goldenberg, M.D., R. Knapp-Clevenger,
More information